Last reviewed · How we verify

aPCC, aPCC + TXA — Competitive Intelligence Brief

aPCC, aPCC + TXA (aPCC, aPCC + TXA) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Prothrombin complex concentrate with antifibrinolytic agent. Area: Hematology / Hemostasis.

marketed Prothrombin complex concentrate with antifibrinolytic agent Vitamin K-dependent clotting factors (II, VII, IX, X); plasminogen Hematology / Hemostasis Small molecule Live · refreshed every 30 min

Target snapshot

aPCC, aPCC + TXA (aPCC, aPCC + TXA) — Oslo University Hospital. aPCC (activated prothrombin complex concentrate) restores coagulation by providing vitamin K-dependent clotting factors, and when combined with TXA (tranexamic acid), is further enhanced by inhibiting fibrinolysis to reduce bleeding.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
aPCC, aPCC + TXA TARGET aPCC, aPCC + TXA Oslo University Hospital marketed Prothrombin complex concentrate with antifibrinolytic agent Vitamin K-dependent clotting factors (II, VII, IX, X); plasminogen

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Prothrombin complex concentrate with antifibrinolytic agent class)

  1. Oslo University Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). aPCC, aPCC + TXA — Competitive Intelligence Brief. https://druglandscape.com/ci/apcc-apcc-txa. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: